Sirolimus-eluting stent treatment as buffer for inflamed lesions identified by serum marker estimation. The STABILISE pilot study.
Khattab
Ahmed A
AA
Röther
Caroline
C
Toelg
Ralph
R
Schwarz
Bettina
B
Mier
Kenneth
K
Geist
Volker
V
Drömann
Daniel
D
Schäfer
Torsten
T
Richardt
Gert
G
D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D002499:Centrifugation, Density Gradient; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D010865:Pilot Projects; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism
D007166:Immunosuppressive Agents; D018950:Lipopolysaccharide Receptors; D008565:Membrane Proteins; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D005340:Fibrinogen; D020123:Sirolimus